Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective in treating mild or moderate COVID-19 illness in adults and adolescents at highest risk for severe outcomes. Each participant will be followed for approximately 28 days.
Epistemonikos ID: 8db0e6434a014280909b33453c84ef209373d3d7
First added on: Dec 15, 2021